Skip to main content

Table 2 Characteristics of patients who underwent PCI and CYP2C19 genotyping over the first 12 months

From: Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention

Characteristic n = 392
Age (years) 63 ± 11
Male sex 271 (69)
Race
 White 292 (74.5)
 Black 93 (23.7)
 Asian 3 (0.8)
 Other or not reported 4 (1.0)
Past medical history
 Stroke or TIA 48 (12.2)
 Gastrointestinal hemorrhage 7 (1.8)
 Intracranial hemorrhage 2 (0.5)
PCI indication
 STEMI 74 (18.9)
 NSTEMI 99 (25.2)
 Unstable angina 174 (44.4)
 Stable coronary disease 45 (11.5)
P2Y12 inhibitor on admission
 Clopidogrel 99 (25.3)
 Prasugrel 9 (2.3)
 Ticagrelor 13 (3.3)
 Other or not available 11 (2.8)
Anticoagulant on admissiona
 Warfarin 9 (2.3)
 Direct oral anticoagulant 12 (3.0)
 Low molecular weight heparin 1 (0.3)
 Not available 9 (2.3)
Anticoagulant at dischargea
 Warfarin 16 (4.1)
 Direct oral anticoagulant 16 (4.1)
 Low molecular weight heparin 1 (0.3)
CYP2C19 phenotype
 Poor metabolizer (*2/*2) 7 (1.8)
 Intermediate metabolizer (*1/*2, *2/*17) 106 (27.0)
 Normal metabolizer (*1/*1) 145 (37.0)
 Rapid metabolizer (*1/*17) 110 (28.1)
 Ultra-rapid metabolizer (*17/*17) 20 (5.1)
 Inconclusive 4 (1.0)
  1. Mean ± SD or no. (%)
  2. PCI percutaneous coronary intervention, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction, TIA transient ischemic attack
  3. aWarfarin, direct oral anticoagulant, or low molecular weight heparin